Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.63 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.63 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.63 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.63 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.63 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8231340 | 1.00 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24066657 | 0.94 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13538057 | 0.94 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12156606 | 0.92 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13307521 | 0.91 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27942343 | 0.87 | CTSB (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL893290 | 0.87 | CYP3A4 (0.62) | — | |
| SCHEMBL30172847 | 0.86 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24066648 | 0.86 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13800208 | 0.85 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960404-B1 | SUBSTITUTED AMINOPHENYLSULFONAMIDE COMPOUNDS AS HIV PROTEASE INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| EP-1960381-B1 | AMINOPHENYLSULFONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITOR | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422780-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8084494-B2 | benzenesulfon-yl]-isobutyl-amino}-1-benzyl-2-hydroxy-propyl)-carbamic Acid hexahydro-furo[2,3-b]furan-3-yl Ester; anti-retroviral agent such as dextran sulfate, suramine etc. AIDS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-12-27 | — | — | US | disclosed |
| US-7807845-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7803836-B2 | Aminophenylsulfonamide derivatives as HIV protease inhibitor | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-09-28 | — | — | US | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| EP-1750696-A4 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1732891-A4 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2007060253-A1 | SUBSTITUTED AMINOPHENYLSULFONAMIDE COMPOUNDS AS HIV PROTEASE INHIBITOR | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2005087728-A9 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1750696-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1732891-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050209301-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005087728-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | PSEN1 377/4885PSEN2 597/4885APH1B 138/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | PSEN1 377/4885PSEN2 597/4885APH1B 138/4885 |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SERPINB1, MMP7, MME | PSEN1 377/4885PSEN2 597/4885APH1B 138/4885 |
| US-20050209301-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | PSEN1 377/4885PSEN2 597/4885APH1B 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.